At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma
In Brief
A Phase 2 clinical trial evaluating 6MHP, NeoAg-mBRAF, and 2 other interventions for Melanoma and 2 related conditions. Completed, enrolled 22 participants across 2 sites.
Detailed Summary
This study evaluates whether it is safe to administer a peptide vaccine made of 6MHP and a mutated neoantigen peptide (BRAF585-614-V600E) combined with adjuvants. The adjuvants that will be used in this trial are a CD40 antibody (CDX-1140) and a toll-like receptor (TLR) 3 agonist (Poly-ICLC). The study will also investigate the effects of the vaccine and the adjuvants on the immune response. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and skin tissue.
Study Details
Timeline
Interventions
6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
BRAF 586-614 (V600E) peptide to which a histidine has been added to the N-terminus, resulting in BRAF 585-614 (V600E).
polyICLC, local adjuvant
CDX-1140, local adjuvant